Table 2.

Summary of patients diagnosed with CML during pregnancy at Hammersmith Hospital, London

Characteristics (N = 11)Median (range); N [%]
Age at diagnosis (years) 33 (25-40) 
Trimester  
 1 6 [55] 
 2 5 [45] 
CML phase  
 Chronic 11 [100] 
WBC ( × 109/L) 80 (14.7-215.4) 
Sokal score  
 Low 6 [55] 
 Intermediate 2 [18] 
 No data 3 [27] 
Pregnancy outcome  
 Live birth 10 [91] 
 Miscarriage 1 [9] 
Management in pregnancy  
 Observation 3 [27] 
 IFNa 2 [18] 
 Leukapheresis 3 [27] 
 IFN + leukapheresis 3 [27] 
TKI started after pregnancy end  
 Imatinib 8 (73) 
 Dasatinib 3 (27) 
Duration of TKI delay (months) 7 (1-10) 
≥MR1 at 3 mo 11 [100] 
≥CCyR at 6 mo 9 [82] 
≥MMR at 12 mo 8 [73] 
Characteristics (N = 11)Median (range); N [%]
Age at diagnosis (years) 33 (25-40) 
Trimester  
 1 6 [55] 
 2 5 [45] 
CML phase  
 Chronic 11 [100] 
WBC ( × 109/L) 80 (14.7-215.4) 
Sokal score  
 Low 6 [55] 
 Intermediate 2 [18] 
 No data 3 [27] 
Pregnancy outcome  
 Live birth 10 [91] 
 Miscarriage 1 [9] 
Management in pregnancy  
 Observation 3 [27] 
 IFNa 2 [18] 
 Leukapheresis 3 [27] 
 IFN + leukapheresis 3 [27] 
TKI started after pregnancy end  
 Imatinib 8 (73) 
 Dasatinib 3 (27) 
Duration of TKI delay (months) 7 (1-10) 
≥MR1 at 3 mo 11 [100] 
≥CCyR at 6 mo 9 [82] 
≥MMR at 12 mo 8 [73] 
a

One patient was switched from IFN-α to PEG-IFN-α due to an adverse reaction to the drug.

or Create an Account

Close Modal
Close Modal